**Core Concept:** Retinoblastoma is a rare cancer that primarily affects the developing eye. It is caused by mutations in the RB1 gene, which leads to uncontrolled cell growth in the retina. Secondary malignancies in patients with retinoblastoma may occur due to prolonged exposure to ionizing radiation or chemotherapy.

**Why the Correct Answer is Right:**
Patients with Retinoblastoma often receive radiation therapy and/or chemotherapy as a part of their treatment. Long-term exposure to these therapies can lead to secondary malignancies, including osteosarcoma (bone cancer). Osteosarcoma is the correct answer because it is a well-known consequence of radiation therapy and is more likely to occur in patients with retinoblastoma compared to other options.

**Why Each Wrong Option is Incorrect:**
A. Lymphoma (Option A) is a rare complication in retinoblastoma patients, while osteosarcoma is more common.
B. Leukemia (Option B) is less likely to occur due to lower exposure to radiation therapy in retinoblastoma patients.
C. Brain tumor (Option C) may result from radiation therapy, but osteosarcoma is a more plausible secondary malignancy in this context.
D. Gastrointestinal cancers (Option D) are uncommon complications of retinoblastoma treatment, while osteosarcoma is a more relevant concern.

**Clinical Pearl:**
Patients with retinoblastoma should receive regular follow-up care to monitor for secondary malignancies. Osteosarcoma is a significant concern due to the potential long-term effects of radiation and chemotherapy. This highlights the importance of considering the specific risks associated with the treatment of rare diseases like retinoblastoma.